{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:46:07Z","timestamp":1792597567003,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can cure selected patients with colorectal peritoneal metastases (CPM). Real-world prognostic data, especially for the Peritoneal Cancer Index (PCI) and completeness of cytoreduction (CCR), are limited. Methods: We retrospectively analysed 75 consecutive patients treated with CRS + HIPEC at a tertiary centre (2014\u20132022), giving \u226536 months potential follow-up. Overall survival (OS) was assessed by Kaplan\u2013Meier and Cox models. PCI was grouped 0\u201310, 11\u201320, &gt;20; CCR was dichotomised (CCR-0 vs. CCR 1\/2). Multivariable analysis included PCI, CCR, and resection extent; HIPEC drug was examined univariately. Results: The median follow-up was 41 months. Crude 3-year OS was 50.7% (38\/75). Survival decreased with higher PCI: 69% for 0\u201310 (n = 42), 38% for 11\u201320 (n = 21), and 0% for &gt; 20 (n = 4). Versus PCI 0\u201310, the adjusted hazard ratios (HR) were 3.02 (95% CI 1.52\u20136.03) for PCI 11\u201320 and 7.29 (1.72\u201330.81) for &gt; 20. CCR-0 improved OS univariately (HR 0.43) but was non-significant after adjustment (HR 0.89). Resection limited to the peritoneum (HR 0.99) and choice of intraperitoneal drug showed no independent effect. Conclusions: In this real-world cohort, PCI was the only independent predictor of 3-year survival after CRS + HIPEC for CPM; neither CCR status, surgical extent, nor HIPEC agent altered prognosis once PCI was considered. PCI should therefore remain the principal selection criterion while molecular and biological markers are integrated into future risk models.<\/jats:p>","DOI":"10.3390\/cancers17223614","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:47:27Z","timestamp":1762775247000},"page":"3614","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Peritoneal Cancer Index Dominates Prognosis After CRS\u2013HIPEC for Colorectal Peritoneal Metastases: A Consecutive Single-Centre Cohort with 3-Year Follow-Up"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8080-3001","authenticated-orcid":false,"given":"Micha\u0142","family":"Kazanowski","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Pulmonology and Hematology, Lower Silesian Center of Oncology, 53-413 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Lesiak","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Pulmonology and Hematology, Lower Silesian Center of Oncology, 53-413 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-8855","authenticated-orcid":false,"given":"J\u0119drzej","family":"Wierzbicki","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Pulmonology and Hematology, Lower Silesian Center of Oncology, 53-413 Wroclaw, Poland"},{"name":"Laboratory of Immunopathology, Department of Experimental Therapy, Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2894-4834","authenticated-orcid":false,"given":"Bartosz","family":"Kapturkiewicz","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Pulmonology and Hematology, Lower Silesian Center of Oncology, 53-413 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Pulmonology and Hematology, Lower Silesian Center of Oncology, 53-413 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Paw\u0142owski","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Pulmonology and Hematology, Lower Silesian Center of Oncology, 53-413 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Jastrz\u0119bski","sequence":"additional","affiliation":[{"name":"Oncological Surgery Department, PCZ Brzeziny Hospital, 95-060 Brzeziny, Poland"},{"name":"Clinic of Gynecology and Obstetrics, Medical University of Gdansk, 80-214 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7376-7286","authenticated-orcid":false,"given":"Marek","family":"B\u0119benek","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Pulmonology and Hematology, Lower Silesian Center of Oncology, 53-413 Wroclaw, Poland"},{"name":"Faculty of Medicine, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s004230050246","article-title":"Management of peritoneal-surface malignancy: The surgeon\u2019s role","volume":"384","author":"Sugarbaker","year":"1999","journal-title":"Langenbeck\u2019s Arch. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","article-title":"Treatment of Colorectal Peritoneal Carcinomatosis with Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841","volume":"30","author":"Franko","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101884","DOI":"10.1016\/j.suronc.2022.101884","article-title":"Do certain surgical steps increase postoperative morbidity after cytoreductive surgery and HIPEC- a retrospective analysis","volume":"45","author":"Riediger","year":"2022","journal-title":"Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients with Peritoneal Carcinomatosis of Colorectal Cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia with Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin","volume":"27","author":"Elias","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/bjc.2014.419","article-title":"Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone","volume":"111","author":"Mirnezami","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.critrevonc.2016.01.017","article-title":"Progress in treatments for colorectal cancer peritoneal metastases during the years 2010\u20132015. A systematic review","volume":"100","author":"Baratti","year":"2016","journal-title":"Crit. Rev. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jamasurg.2021.5024","article-title":"New Insights on the Treatment of Colorectal Peritoneal Metastases from the CAIRO6 Trial","volume":"157","author":"Bhatt","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12957-021-02145-1","article-title":"Thirty-three long-term survivors after cytoreductive surgery in patients with peritoneal metastases from colorectal cancer: A retrospective descriptive study","volume":"19","author":"Kamada","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/codi.15003","article-title":"Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: A systematic review and meta-analysis","volume":"22","author":"Narasimhan","year":"2020","journal-title":"Color. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis from Colorectal Cancer: A Multi-Institutional Study","volume":"22","author":"Glehen","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jso.23431","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer","volume":"108","author":"Gervais","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.ejso.2020.07.039","article-title":"Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"46","author":"Birgisson","year":"2020","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br. J. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1245\/s10434-013-3204-2","article-title":"Comparison of Prognostic Scores for Patients with Colorectal Cancer Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"20","author":"Cashin","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Xia, W., Geng, Y., and Hu, W. (2023). Peritoneal Metastasis: A Dilemma and Challenge in the Treatment of Metastatic Colorectal Cancer. Cancers, 15.","DOI":"10.3390\/cancers15235641"},{"key":"ref_19","first-page":"5180895","article-title":"Colorectal Peritoneal Metastases: A Systematic Review of Current and Emerging Trends in Clinical and Translational Research","volume":"2019","author":"Koumpa","year":"2019","journal-title":"Gastroenterol. Res. Pr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12957-025-03736-y","article-title":"Evaluating long-term outcomes after cytoreductive surgery for colorectal peritoneal metastasis: Do long survivors really exist?","volume":"23","author":"Aulicino","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1245\/s10434-019-07452-2","article-title":"Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC","volume":"27","author":"Graf","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Beagan, J.J., Sluiter, N.R., Bach, S., Eijk, P.P., Vlek, S.L., Heideman, D.A.M., Kusters, M., Pegtel, D.M., Kazemier, G., and van Grieken, N.C.T. (2020). Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061738"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1245\/s10434-016-5211-6","article-title":"Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC","volume":"23","author":"Simkens","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Qiu, B., Shen, Z., Wu, S., Qin, X., Yang, D., and Wang, Q. (2023). A machine learning-based model for predicting distant metastasis in patients with rectal cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1235121"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.ejso.2020.04.018","article-title":"Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study","volume":"46","author":"Bakkers","year":"2020","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1245\/s10434-008-0105-x","article-title":"Multivisceral Resection Does Not Affect Morbidity and Survival After Cytoreductive Surgery and Chemoperfusion for Carcinomatosis from Colorectal Cancer","volume":"15","author":"Franko","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","article-title":"Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?","volume":"249","author":"Chua","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/bjs.10422","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin","volume":"104","author":"Kok","year":"2017","journal-title":"Br. J. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1245\/s10434-019-07957-w","article-title":"Diagnostic Laparoscopy as a Selection Tool for Patients with Colorectal Peritoneal Metastases to Prevent a Non-therapeutic Laparotomy During Cytoreductive Surgery","volume":"27","author":"Hentzen","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kamada, Y., Hida, K., Yonemura, Y., Sugarbaker, P.H., Ghabra, S., Ishihara, S., Nagata, H., Murono, K., Goi, T., and Katayama, K. (2021). The Characteristics of 206 Long-Term Survivors with Peritoneal Metastases from Colorectal Cancer Treated with Curative Intent Surgery: A Multi-Center Cohort from PSOGI. Cancers, 13.","DOI":"10.3390\/cancers13122964"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.23922\/jarc.2020-033","article-title":"Investigation of the Japanese Classification of Peritoneal Metastasis from Colorectal Cancer Referring to the Correlation with PCI","volume":"4","author":"Kawasaki","year":"2020","journal-title":"J. Anus, Rectum Colon"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1245\/s10434-020-09161-7","article-title":"Prognostic Impact of Primary Side and RAS\/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases","volume":"28","author":"Baratti","year":"2020","journal-title":"Ann. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3614\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:56:38Z","timestamp":1762775798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":33,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17223614"],"URL":"https:\/\/doi.org\/10.3390\/cancers17223614","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}